Persistent Epithelial Defect Management Market Report 2026

The persistent epithelial defect management market size has grown rapidly in recent years. It will grow from $9.26 billion in 2025 to $10.82 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to limited awareness of persistent epithelial defects, reliance on conventional lubricating eye drops, slow adoption of autologous serum therapy, inadequate access to corneal specialists, inconsistent follow-up and patient monitoring.

The persistent epithelial defect management market size is expected to see rapid growth in the next few years. It will grow to $19.94 billion in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to advancements in stem cell and biologic therapies, rising adoption of amniotic membrane transplantation, increasing preference for bandage contact lenses, growing awareness about early corneal defect management, expansion of hospital and specialized eye care centers. Major trends in the forecast period include rising adoption of ai-powered diagnostic and imaging tools, increasing use of biologics and stem cell therapies, integration of cloud-based patient monitoring systems, development of iot-enabled eye care devices, advancements in automated manufacturing of ocular therapeutics.

The increasing prevalence of eye disorders is expected to support the growth of the persistent epithelial defect management market in the coming years. Eye disorders encompass a wide range of medical conditions that affect the structure, function, or overall health of the eyes, often resulting in visual impairment, discomfort, or potential vision loss. The growing incidence of eye disorders is largely driven by factors such as aging populations, extended screen exposure, and changing environmental conditions. Persistent epithelial defect management plays a critical role in addressing eye disorders by promoting corneal healing, reducing inflammation, and preventing complications such as infections or scarring. For instance, in December 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, the pooled global prevalence of childhood myopia was 5.23% in 2023, with a higher prevalence observed among females at 4.90% compared to males at 3.94%. Therefore, the rising prevalence of eye disorders is contributing to the growth of the persistent epithelial defect management market.

The increasing number of eye surgeries is also expected to drive the growth of the persistent epithelial defect management market going forward. Eye surgeries are medical procedures performed to correct vision impairments, treat ocular diseases, or repair eye injuries. The growth in eye surgeries is attributed to the rising burden of conditions such as cataracts, glaucoma, and refractive errors, along with advancements in surgical techniques and the expanding use of minimally invasive procedures. Persistent epithelial defect management supports post-surgical recovery by enhancing corneal healing, minimizing complications, and improving visual outcomes through targeted therapies that aid epithelial regeneration. For example, in 2023, according to the Eye Bank Association of America, a US-based transplant association, the number of domestic keratoplasty procedures increased by 2.7%, rising from 49,597 in 2022 to 50,925 in 2023. Therefore, the rise in eye surgeries is driving the growth of the persistent epithelial defect management market.

Major companies operating in the persistent epithelial defect management market are prioritizing the development of advanced therapies, including secretome-based treatments, to accelerate healing and enhance clinical outcomes for patients with persistent epithelial defects. Secretome therapy involves the use of bioactive substances released by cells, such as proteins, lipids, and extracellular vesicles, to stimulate tissue repair, regulate immune responses, and treat various medical conditions. For instance, in April 2023, Kala Pharmaceuticals Inc., a US-based biopharmaceutical company, received Fast Track Designation from the US Food and Drug Administration for KPI-012, a human mesenchymal stem cell secretome therapy for persistent corneal epithelial defect. This therapy employs a multifaceted mechanism of action to address underlying causes of persistent epithelial defects by promoting corneal repair through bioactive components such as growth factors, protease inhibitors, and neurotrophic factors.

Major companies operating in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompé Farmaceutici S.p.A., TissueTech Inc., Ocular Therapeutix Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc., Kala Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc., Aldeyra Therapeutics Inc.

North America was the largest region in the persistent epithelial defect management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the persistent epithelial defect management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the persistent epithelial defect management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the persistent epithelial defect management market by increasing costs for imported biologics, amniotic membranes, and specialized ocular devices, particularly affecting hospitals, clinical laboratories, and physician offices in North America and Europe. While tariffs have temporarily raised treatment expenses, they have also encouraged local production, alternative sourcing strategies, and innovation in cost-efficient ocular therapeutics, ultimately supporting long-term market growth.

The persistent epithelial defect management market research report is one of a series of new reports that provides persistent epithelial defect management market statistics, including persistent epithelial defect management industry global market size, regional shares, competitors with a persistent epithelial defect management market share, detailed persistent epithelial defect management market segments, market trends and opportunities, and any further data you may need to thrive in the persistent epithelial defect management industry. This persistent epithelial defect management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Persistent epithelial defect (PED) management involves medical approaches aimed at supporting corneal healing when the corneal epithelium does not regenerate and close within two weeks despite standard therapy. It focuses on identifying and treating underlying causes through therapeutic methods such as lubricating eye drops, autologous serum tears, amniotic membrane transplantation, bandage contact lenses, and biologic therapies to promote epithelial repair and prevent corneal complications including ulcers or perforation.

The primary disease types addressed in persistent epithelial defect management include epithelial or limbal conditions, inflammatory diseases, neurotrophic diseases, and other disease categories. Epithelial and limbal conditions impact the corneal epithelium and limbal stem cells, resulting in vision-threatening defects due to compromised corneal regeneration. Drugs are supplied through multiple distribution channels, including direct sales, online pharmacies, retail pharmacies, and hospitals. These treatments are utilized by a range of end users such as hospital or clinical laboratories, physician offices, reference laboratories, and other end users.

The persistent epithelial defect management market consists of revenues earned by entities by providing services such as pharmacological treatments, amniotic membrane transplantation, bandage contact lenses, and tarsorrhaphy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The persistent epithelial defect management market also includes sales of autologous serum eye drops, regenerative biologic eye drops, bandage contact lenses, and amniotic membrane grafts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.